Facet-Joint Injection Global Market Report 2025

The facet-joint injection market size has grown strongly in recent years. It will grow from $2.78 billion in 2024 to $2.97 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth observed during the historic period can be attributed to the increasing incidence of chronic back and neck pain, greater adoption of minimally invasive pain treatments, an aging population experiencing spinal degeneration, improved access to image-guided injection techniques, and heightened awareness of non-surgical pain relief methods.

The facet-joint injection market size is expected to see strong growth in the next few years. It will grow to $3.85 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The projected growth in the forecast period is driven by rising demand for non-opioid pain management options, greater adoption of image-guided injection technologies, increased emphasis on outpatient and day-care procedures, expanded use of regenerative injection therapies, and growing healthcare investments in treatments for spinal disorders. Key trends expected during this time include improvements in ultrasound and fluoroscopy-guided injections, development of advanced drug formulations for longer-lasting pain relief, creation of combination therapies for joint pain, innovations in regenerative treatments like platelet-rich plasma and stem cells, and progress in wearable technology for monitoring after injections.

The increasing prevalence of spinal diseases and chronic back pain is expected to drive the growth of the facet-joint injection market going forward. These conditions, which include disc degeneration, arthritis, and nerve compression, cause ongoing pain, limited mobility, and a lower quality of life. The rise in spinal diseases and chronic back pain is largely attributed to sedentary lifestyles and poor posture, prompting more individuals to seek effective, minimally disruptive treatments that alleviate persistent discomfort and restore movement. Facet-joint injections provide relief by reducing pain and inflammation in the spine, helping those affected by these growing spinal health issues. For example, in May 2023, Spinal Cord Inc., a U.S.-based non-profit resource center, reported that approximately 18,000 new spinal cord injury cases occur annually in the United States, with an estimated 302,000 people living with spinal cord injuries nationwide. As a result, the increasing prevalence of spinal diseases and chronic back pain is fueling the expansion of the facet-joint injection market.

The increasing demand for minimally invasive procedures is expected to drive the growth of the facet-joint injection market in the coming years. Minimally invasive procedures involve medical treatments performed through small incisions or without large surgical cuts. Their popularity is rising due to patients’ preference for quicker recovery and less post-operative pain. Facet-joint injections support these procedures by offering precise pain relief and diagnostic clarity without requiring extensive surgery. For example, in 2023, the American Society of Plastic Surgeons, a U.S.-based specialty organization, reported that the number of minimally invasive cosmetic procedures increased from 23.7 million in 2022 to 25.4 million in 2023. Consequently, the growing demand for minimally invasive treatments is fueling the expansion of the facet-joint injection market.

Key players in the facet-joint injection market are concentrating on creating innovative solutions, such as facet fusion systems, to provide longer-lasting relief and enhance treatment effectiveness. Facet fusion systems are medical devices designed to stabilize and fuse the facet joints by encouraging bone growth between neighboring vertebrae. For example, in March 2025, Aurora Spine Corporation, a U.S.-based medical device manufacturer, announced that its latest product, the AERO™ Facet Fusion System, received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This system features a titanium plasma spray coating to enhance osseointegration and fusion potential. It also offers multiple implant sizes to fit different patient anatomies and includes radiolucent instruments to improve visibility during surgery. Together, these features aim to increase procedural efficiency and improve long-term outcomes in the treatment of chronic back pain caused by facet joint disorders.

Major players in the facet-joint injection market are Pfizer Inc., Merck & Co. Inc, AbbVie Inc., Sanofi S.A., Medtronic plc, Stryker Corporation, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Henry Schein Inc., Bausch Health Companies Inc., Zimmer Biomet Holdings Inc., Smith & Nephew plc, Dr. Reddy’s Laboratories Ltd., Arthrex Inc., Aspen Pharmacare Holdings Limited, Pacira BioSciences Inc., Bioventus Inc., Ferring Pharmaceuticals, Anika Therapeutics Inc., Symbiotec Pharmalab Pvt. Ltd.

North America was the largest region in the facet-joint injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in facet-joint injection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the facet-joint injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A facet joint injection is a minimally invasive procedure designed to diagnose or treat pain originating from the facet joints, which are small joints located between pairs of vertebrae in the spine. The injection usually contains a mix of a local anesthetic to numb the area and a corticosteroid to reduce inflammation. This procedure is often used to alleviate chronic pain in the neck, back, or thoracic region caused by arthritis or spinal degeneration.

The primary types of products used in facet joint injections include corticosteroids, local anesthetics, hyaluronic acid, and others. Corticosteroids are steroid hormones utilized medically to decrease inflammation and suppress immune responses. These injections are applied to various regions such as the cervical, thoracic, and lumbar facet joints, and are administered by a range of end-users including hospitals, ambulatory surgical centers, specialty clinics, and more.

The facet-joint injection market research report is one of a series of new reports that provides facet-joint injection market statistics, including the facet-joint injection industry global market size, regional shares, competitors with the facet-joint injection market share, detailed facet-joint injection market segments, market trends, and opportunities, and any further data you may need to thrive in the facet-joint injection industry. This facet-joint injection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The facet-joint injection market consists of revenues earned by entities through medication management, rehabilitation and psychological counseling, and interventional procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The facet-joint injection market also includes of sales of injection kits, imaging guidance systems, patient monitoring devices, and pain-relieving medications. Values in this market are ‘factory gate’ values, meaning the value of goods sold by the manufacturers or creators, whether to other companies (like distributors, clinics, and hospitals) or directly to end users. The value of goods in this market also includes related services provided by the creators, such as training or support for the use of injection products.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.